Milestone advances in the development and evaluation of plasma (Aβ1–42 and neurofilament light concentrations) and CSF biomarkers (Aβ1–42, total-tau, p-tau concentrations) have also revolutionized the prospect of early diagnosis for AD (Hampel et al., 2018; Baldacci et al., 2020). In general, both categories of fluid biomarkers have proven superior to the majority of currently available brain scanning tools with regards to sensitivity, accessibility and cost-effectiveness. Yet, CSF extraction remains an invasive approach and plasma markers are subject to interference from other bodily organs and peripheral metabolic processes, and therefore may not be able to solely represent the underlying neuropathological events occurring in the brain (Johnson K.A. et al., 2012). These challenges provide great incentive to explore other diagnostic methods for deployment in the general population, perhaps through another CNS tissue – the retina.